Immunic closed at $7.94 on Nov 4, up 4.47%, 91.0% below its 52-week closing high. Volume of 175.4K shares was 0.49× its 20-day average (below normal).
Split-adjusted performance: +1.5% over one month, -27.9% over six months, +6.1% over one year.
Short interest was 1.9M shares at the Oct 15 settlement, down 10.3% from the prior report (17.5% of float, 4.1 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| IMUXImmunic | $7.94 | +4.47% | −27.9% | — | — | — | $108.3M | |
| NRXPNRX Pharmaceuticals | $2.49 | +11.16% | −18.4% | — | −1500.5% | — | $107.8M | Compare |
| HURATuHURA Biosciences | $1.72 | +3.93% | −32.3% | — | — | — | $109.6M | Compare |
| EQEquillium | $1.40 | −0.71% | −35.5% | — | — | — | $109.7M | Compare |
| OKUROnKure Therapeutics | $2.59 | +3.60% | −36.4% | — | — | — | $104.9M | Compare |
| ORGOOrganogenesis Holdings | $0.8700 | +4.19% | −66.0% | −56.7% | −227.0% | — | $111.9M | Compare |
| UNCYUnicycive Therapeutics | $3.75 | +4.46% | −53.9% | — | — | — | $104.5M | Compare |
| ANIXAnixa Biosciences | $3.28 | +7.37% | +7.2% | — | — | — | $114.0M | Compare |
| CATXPerspective Therapeutics | $0.8702 | −1.11% | −77.2% | −72.1% | −33069.1% | — | $99.3M | Compare |
No recent articles focused on Immunic. 1 articles mention it in passing.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
